Soleno and Acadias drugs for PWS specifically target hyperphagia whereas NNZ2591 impacts the syndrome broadly. As our two drugs do for all 6 syndromes we currently target and the infinite number thereafter…. There is no reason our drug cannot be taken in conjunction with the others to treat PWS.
These are not the exact words JP used when I asked him … but it summarises his thoughts.
Bring on 2024!
Neuren Media and Analyst Coverage, page-644
-
- There are more pages in this discussion • 756 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.25 |
Change
-0.100(0.81%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.25 | $12.02 | $3.677M | 302.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1579 | $12.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.26 | 1199 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |